STOCK TITAN

Cellectis S.A. - $CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis S.A. news (Ticker: $CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. stock.

Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.

Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.

Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.

Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.

For more information, visit the company's website at www.cellectis.com.

Rhea-AI Summary

Cellectis announced a breakthrough in gene therapy for Sickle Cell Disease (SCD) using a non-viral approach published in Nature Communications. The therapy employs TALEN® technology for precise HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). This method achieves over 50% expression of normal hemoglobin in treated cells, effectively correcting the sickle cell phenotype without adverse effects. The preclinical data shows promising therapeutic potential and efficient engraftment in animal models, indicating readiness for clinical application. This innovative approach offers hope for addressing SCD and other genetic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary

Cellectis has released its monthly update on share capital and voting rights as of May 31, 2024. The company, listed on Euronext Growth with ISIN code FR0010425595, reports a total of 100,093,635 shares in its capital. The number of voting rights stands at 88,029,374. For more details, media and investor relations contacts are provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
-
Rhea-AI Summary

Cellectis announced that the European Commission granted Orphan Drug Designation (ODD) to UCART22, its allogeneic CAR T product for treating Acute Lymphoblastic Leukemia (ALL).

UCART22 targets CD22 and is being evaluated in the Phase 1/2 BALLI-01 study, focusing on patients with relapsed/refractory ALL.

ALL accounts for 12% of all leukemia cases and progresses rapidly. The 10-year prevalence in the EU is estimated at 1.9 per 100,000 persons.

The ODD was based on preliminary clinical data showing UCART22's significant benefit in heavily pretreated patients. In December 2023, Cellectis reported encouraging data with a 67% response rate at Dose Level 2 for UCART22-P2.

ODD provides regulatory, financial, and commercial incentives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.23%
Tags
Rhea-AI Summary

Cellectis (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET.

The meeting will take place at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Details regarding the agenda and participation are available on the Cellectis website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Summary

Cellectis reported its Q1 2024 financial results revealing key business updates and financial highlights. Key points include:

Completion of a $140M equity investment by AstraZeneca, pushing the company's cash position to $143M as of March 31, 2024, and extending its cash runway projection into 2026.

Revenues for Q1 2024 were $6.5M, a significant increase from $3.6M in Q1 2023.

R&D expenses rose to $22.3M from $21.1M, while SG&A expenses were relatively stable at $5.1M.

The company recorded a consolidated net income of $5.6M, compared to a net loss of $30.1M in Q1 2023.

Key clinical programs BALLI-01, NATHALI-01, and AMELI-01 continue to progress with updates expected by year-end 2024.

The appointment of Arthur Stril as Interim CFO was announced, and AstraZeneca now owns approximately 44% of Cellectis' share capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
-
Rhea-AI Summary

Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company specializing in gene-editing platform technologies, will announce its first quarter 2024 financial results on May 28, 2024, after the US market closes. The results will cover the period ending March 31, 2024. Following the announcement, the Company will hold an investor conference call and webcast on May 29, 2024, at 8:00 AM ET / 2:00 PM CET to discuss the financial results and provide an update on business activities. Investors and stakeholders can join the call using the provided domestic and international dial-in numbers or access the webcast online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences earnings
Rhea-AI Summary

On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority. The company, listed on Euronext Growth under the ISIN code FR0010425595, reported a total of 99,955,535 shares in its capital and 87,891,239 voting rights as of May 3, 2024. For more details, the company provided contact information for their media and investor relations teams.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary

In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
none
-
Rhea-AI Summary

Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.04%
Tags
none
Rhea-AI Summary

Cellectis appointed Arthur Stril as the interim Chief Financial Officer, replacing Bing Wang. Mr. Stril, with a strong background in finance and business development, will oversee finance, investor relations, and business development functions. His appointment comes at a critical growth phase for Cellectis, as they advance their pipeline of assets and explore new opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What does Cellectis S.A. specialize in?

Cellectis S.A. specializes in developing cancer immunotherapies using gene-edited T-cells, known as UCART.

What proprietary technologies does Cellectis use?

Cellectis uses its proprietary TALEN® technology and PulseAgile electroporation system for gene editing.

What are UCART cells?

UCART cells are allogeneic Chimeric Antigen Receptor T-cells developed to target and eradicate cancer cells.

What recent advancements has Cellectis made?

Cellectis has introduced a novel method for circularizing non-viral single-strand DNA templates to enhance gene editing outcomes in HSPCs.

Which companies has Cellectis partnered with?

Cellectis has partnership agreements with companies like AstraZeneca, expanding its pipeline of allogeneic CAR T-cell therapies.

On which stock markets is Cellectis listed?

Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets.

What are HSPCs?

HSPCs are hematopoietic stem and progenitor cells, which Cellectis gene-edits for various therapeutic applications.

How long has Cellectis been in the gene editing field?

Cellectis has over 18 years of expertise in the gene editing field.

Where can I find more information about Cellectis?

More information about Cellectis can be found on their website at www.cellectis.com.

How does Cellectis contribute to immuno-oncology?

Cellectis develops innovative immuno-oncology therapies by harnessing the power of gene-edited T-cells to fight cancer.

Cellectis S.A.

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

161.90M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Paris